Developer docs
API playgroundTry for free, no card

Search company profiles

HistoTox Labs

Full company profile

uuid0028l9c

Namestring
HistoTox Labs
Legal namestring
Inotiv, Inc.
Company typeenum
Public
Founded yearint
2021
Descriptiontext

HistoTox Labs is a Boulder, Colorado-based provider of histology and histopathology services, founded in 2003. The firm operates as a specialized service line within the broader Inotiv, Inc. (NASDAQ: NOTV) discovery and development contract research organization (CRO) platform, which was formed in 2021 through the merger of Covance's Research Models and Services business with Envigo. HistoTox Labs delivers tissue processing, histology, and pathology services that support drug discovery and nonclinical development, with capabilities spanning histochemistry, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and stereology. Its primary buyer base includes pharmaceutical and biotechnology companies, government agencies, and academic research institutions that require GLP-compliant testing for IND-enabling studies and regulatory submissions.

The company's core technical platform centers on whole slide imaging combined with AI-driven quantitative image analysis, enabling automated and reproducible pathology assessment. Supporting infrastructure includes the proprietary Eusoft Labs laboratory information management system (LIMS) and LabTracks research model tracking software, both of which integrate laboratory data and workflow management. Adjacent capabilities include DMPK (in vitro and in vivo), safety pharmacology, genetic toxicology, developmental and reproductive toxicology, carcinogenicity studies, bioanalysis for small and large molecules, SEND-compliant reporting, predictive and computational toxicology, and medical device testing. Recent product expansions include Cell and Gene Therapy safety assessment and mass spectrometry assays covering 27 antibody-drug conjugate target proteins for oncology and other therapeutic applications.

Commercially, HistoTox Labs generates revenue through project-based service contracts as part of Inotiv's CRO portfolio, with the broader platform reporting $120.9 million in Q1 FY2026 revenue (up 0.8% year-over-year) and securing $65 million in new money financing commitments in June 2026. Distribution relies primarily on direct enterprise field sales targeting scientific decision-makers at pharmaceutical, biotech, government, and academic buyers, supported by scientific content marketing, conference presence (e.g., Society of Toxicologic Pathologists, International Conference on Environmental Mutagens), webinars, and downloadable technical resources. Pricing is quote-based rather than publicly disclosed, consistent with multi-year program contracts typical of regulated nonclinical research outsourcing.

Short descriptiontext

HistoTox Labs provides histology and histopathology services, including digital pathology with AI-driven image analysis, supporting pharmaceutical, biotech, government, and academic clients in drug discovery and nonclinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
histology services, histopathology services, preclinical research, contract research, digital pathology
Industry4 codes
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Contract Research / Preclinical Laboratory Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Discovery and Development Services
TypeProfessional Services
Description

Contract research organization providing nonclinical and analytical services including toxicology, DMPK, histology, pathology, and bioanalysis. Revenue generated through project-based service contracts with pharmaceutical and biotech companies, government agencies, and academic institutions.

inotiv.com
2Research Models and Services
TypeHardware Sales
Description

Sale of research models (animals) and related services including genetically engineered models, contract breeding, surgical services, and genetic testing. Revenue from model sales and associated support services.

inotiv.com
3Teklad Laboratory Animal Products
TypeHardware Sales
Description

Laboratory animal diets, bedding, and environmental enrichment products sold to research institutions and pharmaceutical companies.

inotiv.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom research services and models are priced based on project scope and requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Contact sales for custom quotes; research model pricing available via downloadable product guide

inotiv.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Teklad
Description

Laboratory animal diets, bedding, and enrichment products

inotiv.com
+2 more records
Core offering1 text field

HistoTox Labs is engaged in providing histology and histopathology services. The broader portfolio evidenced includes industry-leading histology laboratories, digital pathology with whole slide imaging and AI-driven quantitative image analysis, toxicology, drug metabolism and pharmacokinetics (DMPK), safety assessment, predictive and computational toxicology, discovery bioanalysis and biomarkers, and a comprehensive range of research models, served by an integrated discovery-through-clinical-development service model.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

HistoTox Labs operates as a discovery and development contract research organization (CRO) offering a comprehensive suite of laboratory services. The portfolio centers on histology, pathology, and toxicology services, including Digital Pathology with AI-driven image analysis, integrated with broader discovery services such as DMPK, safety assessment, and research models. Core offerings include Histology and Pathology Services, Digital Pathology, Toxicology Services, DMPK, Predictive and Computational Toxicology, Safety Assessment, Discovery Bioanalysis and Biomarkers, and Research Models, supported by add-on data management tools Eusoft Labs (LIMS) and LabTracks.

Product and service9 records
1Histology and Pathology Services
CategoryLaboratory Services
Description

Histology laboratory services supporting discovery and nonclinical development projects, covering a wide range of capabilities from tissue processing to digital analysis for pharmaceutical, biotech, government, and academic clients.

2Digital Pathology
CategoryDigital Pathology / Imaging
Description

Whole slide imaging combined with precision AI-driven quantitative image analysis to support drug discovery and development projects.

3Toxicology Services
CategorySafety Assessment
Description

General toxicology studies to evaluate the safety of drugs, medical devices, and other chemicals in accordance with international regulations (including GLP and non-GLP).

4Drug Metabolism and Pharmacokinetics (DMPK)
CategoryDrug Metabolism and Pharmacokinetics
Description

In vitro and in vivo studies along with bioanalytical solutions spanning hit-to-lead through candidate selection.

5Pathology Services
CategoryPathology Services
Description

World-class anatomical, clinical, and medical device pathology team providing services from histochemistry to digital pathology, including IHC, IF, ISH, and stereology.

6Predictive and Computational Toxicology
CategoryComputational Toxicology
Description

Computational approaches to predict and assess toxicological profiles of compounds.

7Safety Assessment
CategorySafety Assessment
Description

Comprehensive safety assessment services integrating toxicology, pathology, bioanalysis, and program management.

8Discovery Bioanalysis and Biomarkers
CategoryBioanalytical Services
Description

Bioanalytical services supporting discovery phases, including biomarker analysis capabilities.

9Research Models
CategoryResearch Models
Description

A comprehensive range of research models for pharmaceutical and biotech companies, government, academia, and life science organizations, including genetically engineered models and services (GEMS), contract breeding, surgical services, and genetic testing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Inotiv is a publicly traded discovery and safety-assessment CRO with significant histopathology and digital pathology capabilities. It is comparable to HistoTox Labs as a histopathology service provider but operates at materially larger scale and across a broader service portfolio.

2Histo-Scientific Research Laboratories (HSRL)
TypeDirect peer
Description

HSRL is a small, specialized histopathology and toxicologic pathology laboratory serving government, academic, and biopharma clients. It is directly comparable to HistoTox Labs in scale, focus, and customer profile as a niche GLP-grade tissue analysis provider.

TypeBroad incumbent
Description

Labcorp Drug Development operates a global nonclinical CRO business that includes histopathology and anatomic pathology support for regulated studies. It is comparable to HistoTox Labs in the same histopathology service category but at vastly greater scale.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO with preclinical pathology and toxicology services supporting drug development. It overlaps with HistoTox Labs' histopathology focus but competes primarily at much larger contract scale and across broader geographies.

5Seventh Wave Laboratories
TypeDirect peer
Description

Seventh Wave is a small preclinical CRO with core capabilities in safety assessment, pharmacology, and pathology. It is comparable to HistoTox Labs as a similarly sized specialty lab serving pharmaceutical R&D clients with tissue-based endpoints.

6Tox Path Specialists
TypeDirect peer
Description

Tox Path Specialists is a veterinary and toxicologic pathology consultancy providing histopathology, peer review, and study support. It is closely comparable to HistoTox Labs as a small specialist in tissue-based toxicology analysis for regulated research.

TypeDirect peer
Description

EPL provides preclinical and toxicologic pathology services, including histology, immunohistochemistry, and peer review for regulated studies. Like HistoTox Labs, it is a focused pathology lab serving pharmaceutical and chemical industry safety programs.

TypeBroad incumbent
Description

Charles River is a large global CRO with established histology and pathology offerings within its safety assessment and research models services. It overlaps with HistoTox Labs in tissue-based preclinical analysis but serves a much broader customer base.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HistoTox Labs

Contract Research / Preclinical Laboratory Serviceshistotoxlabs.com

HistoTox Labs provides histology and histopathology services, including digital pathology with AI-driven image analysis, supporting pharmaceutical, biotech, government, and academic clients in drug discovery and nonclinical development.

What HistoTox Labs does

HistoTox Labs is a Boulder, Colorado-based provider of histology and histopathology services, founded in 2003. The firm operates as a specialized service line within the broader Inotiv, Inc. (NASDAQ: NOTV) discovery and development contract research organization (CRO) platform, which was formed in 2021 through the merger of Covance's Research Models and Services business with Envigo. HistoTox Labs delivers tissue processing, histology, and pathology services that support drug discovery and nonclinical development, with capabilities spanning histochemistry, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and stereology. Its primary buyer base includes pharmaceutical and biotechnology companies, government agencies, and academic research institutions that require GLP-compliant testing for IND-enabling studies and regulatory submissions.

The company's core technical platform centers on whole slide imaging combined with AI-driven quantitative image analysis, enabling automated and reproducible pathology assessment. Supporting infrastructure includes the proprietary Eusoft Labs laboratory information management system (LIMS) and LabTracks research model tracking software, both of which integrate laboratory data and workflow management. Adjacent capabilities include DMPK (in vitro and in vivo), safety pharmacology, genetic toxicology, developmental and reproductive toxicology, carcinogenicity studies, bioanalysis for small and large molecules, SEND-compliant reporting, predictive and computational toxicology, and medical device testing. Recent product expansions include Cell and Gene Therapy safety assessment and mass spectrometry assays covering 27 antibody-drug conjugate target proteins for oncology and other therapeutic applications.

Commercially, HistoTox Labs generates revenue through project-based service contracts as part of Inotiv's CRO portfolio, with the broader platform reporting $120.9 million in Q1 FY2026 revenue (up 0.8% year-over-year) and securing $65 million in new money financing commitments in June 2026. Distribution relies primarily on direct enterprise field sales targeting scientific decision-makers at pharmaceutical, biotech, government, and academic buyers, supported by scientific content marketing, conference presence (e.g., Society of Toxicologic Pathologists, International Conference on Environmental Mutagens), webinars, and downloadable technical resources. Pricing is quote-based rather than publicly disclosed, consistent with multi-year program contracts typical of regulated nonclinical research outsourcing.

HistoTox Labs firmographics

Firmographics
Name
HistoTox Labs
Legal name
Inotiv, Inc.
Website
https://histotoxlabs.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
501–1,000 employees
Short description
HistoTox Labs provides histology and histopathology services, including digital pathology with AI-driven image analysis, supporting pharmaceutical, biotech, government, and academic clients in drug discovery and nonclinical development.
Ownership category
akta.pro rank

HistoTox Labs industry classification

Industry
Product category
Contract Research / Preclinical Laboratory Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAEAC
Anatomic Pathology & Histopathology (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)

Keywords

  • Histology services
  • Histopathology services
  • Preclinical research
  • Contract research
  • Digital pathology

Where HistoTox Labs is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices2 records

Markets served

HistoTox Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Discovery and Development Services: Contract research organization providing nonclinical and analytical services including toxicology, DMPK, histology, pathology, and bioanalysis. Revenue generated through project-based service contracts with pharmaceutical and biotech companies, government agencies, and academic institutions.
  2. Research Models and Services: Sale of research models (animals) and related services including genetically engineered models, contract breeding, surgical services, and genetic testing. Revenue from model sales and associated support services.
  3. Teklad Laboratory Animal Products: Laboratory animal diets, bedding, and environmental enrichment products sold to research institutions and pharmaceutical companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom research services and models are priced based on project scope and requirements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

HistoTox Labs product offering

Product offering

Core offering

HistoTox Labs is engaged in providing histology and histopathology services. The broader portfolio evidenced includes industry-leading histology laboratories, digital pathology with whole slide imaging and AI-driven quantitative image analysis, toxicology, drug metabolism and pharmacokinetics (DMPK), safety assessment, predictive and computational toxicology, discovery bioanalysis and biomarkers, and a comprehensive range of research models, served by an integrated discovery-through-clinical-development service model.

Product overview

HistoTox Labs operates as a discovery and development contract research organization (CRO) offering a comprehensive suite of laboratory services. The portfolio centers on histology, pathology, and toxicology services, including Digital Pathology with AI-driven image analysis, integrated with broader discovery services such as DMPK, safety assessment, and research models. Core offerings include Histology and Pathology Services, Digital Pathology, Toxicology Services, DMPK, Predictive and Computational Toxicology, Safety Assessment, Discovery Bioanalysis and Biomarkers, and Research Models, supported by add-on data management tools Eusoft Labs (LIMS) and LabTracks.

Differentiator

Problem solved

Functional benefit

Brands

  • Teklad: Laboratory animal diets, bedding, and enrichment products
  • Eusoft Labs
  • LabTracks

Products and services

  • Histology and Pathology Services Histology laboratory services supporting discovery and nonclinical development projects, covering a wide range of capabilities from tissue processing to digital analysis for pharmaceutical, biotech, government, and academic clients.
  • Digital Pathology Whole slide imaging combined with precision AI-driven quantitative image analysis to support drug discovery and development projects.
  • Toxicology Services General toxicology studies to evaluate the safety of drugs, medical devices, and other chemicals in accordance with international regulations (including GLP and non-GLP).
  • Drug Metabolism and Pharmacokinetics (DMPK) In vitro and in vivo studies along with bioanalytical solutions spanning hit-to-lead through candidate selection.
  • Pathology Services World-class anatomical, clinical, and medical device pathology team providing services from histochemistry to digital pathology, including IHC, IF, ISH, and stereology.
  • Predictive and Computational Toxicology Computational approaches to predict and assess toxicological profiles of compounds.
  • Safety Assessment Comprehensive safety assessment services integrating toxicology, pathology, bioanalysis, and program management.
  • Discovery Bioanalysis and Biomarkers Bioanalytical services supporting discovery phases, including biomarker analysis capabilities.
  • Research Models A comprehensive range of research models for pharmaceutical and biotech companies, government, academia, and life science organizations, including genetically engineered models and services (GEMS), contract breeding, surgical services, and genetic testing.

Companies that use HistoTox Labs

Customer profile

Segments4 records

Ideal customer profiles2 records

HistoTox Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

HistoTox Labs partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

HistoTox Labs competitors and assessment

Company assessment

Broad incumbents

  • Inotiv: Inotiv is a publicly traded discovery and safety-assessment CRO with significant histopathology and digital pathology capabilities. It is comparable to HistoTox Labs as a histopathology service provider but operates at materially larger scale and across a broader service portfolio.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development operates a global nonclinical CRO business that includes histopathology and anatomic pathology support for regulated studies. It is comparable to HistoTox Labs in the same histopathology service category but at vastly greater scale.
  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO with preclinical pathology and toxicology services supporting drug development. It overlaps with HistoTox Labs' histopathology focus but competes primarily at much larger contract scale and across broader geographies.
  • Charles River Laboratories: Charles River is a large global CRO with established histology and pathology offerings within its safety assessment and research models services. It overlaps with HistoTox Labs in tissue-based preclinical analysis but serves a much broader customer base.

Direct peers

  • Histo-Scientific Research Laboratories (HSRL): HSRL is a small, specialized histopathology and toxicologic pathology laboratory serving government, academic, and biopharma clients. It is directly comparable to HistoTox Labs in scale, focus, and customer profile as a niche GLP-grade tissue analysis provider.
  • Seventh Wave Laboratories: Seventh Wave is a small preclinical CRO with core capabilities in safety assessment, pharmacology, and pathology. It is comparable to HistoTox Labs as a similarly sized specialty lab serving pharmaceutical R&D clients with tissue-based endpoints.
  • Tox Path Specialists: Tox Path Specialists is a veterinary and toxicologic pathology consultancy providing histopathology, peer review, and study support. It is closely comparable to HistoTox Labs as a small specialist in tissue-based toxicology analysis for regulated research.
  • Experimental Pathology Laboratories (EPL): EPL provides preclinical and toxicologic pathology services, including histology, immunohistochemistry, and peer review for regulated studies. Like HistoTox Labs, it is a focused pathology lab serving pharmaceutical and chemical industry safety programs.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat6 records

Key risks3 records

Key highlights4 records

Customer concentration

HistoTox Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HistoTox Labs leadership team

Management profile

Number of profiles

HistoTox Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HistoTox Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HistoTox Labs

What does HistoTox Labs do?

HistoTox Labs is engaged in providing histology and histopathology services. The broader portfolio evidenced includes industry-leading histology laboratories, digital pathology with whole slide imaging and AI-driven quantitative image analysis, toxicology, drug metabolism and pharmacokinetics (DMPK), safety assessment, predictive and computational toxicology, discovery bioanalysis and biomarkers, and a comprehensive range of research models, served by an integrated discovery-through-clinical-development service model.

Is HistoTox Labs a public or private company?

HistoTox Labs is a public company. It is classified as unknown and is currently operating.

When was HistoTox Labs founded?

HistoTox Labs was founded in 2021. It employs 501 to 1,000 people.

Where is HistoTox Labs based?

HistoTox Labs is headquartered in Boulder, United States, in the North America region.

How does HistoTox Labs make money?

Three revenue lines are on record. Discovery and Development Services are the primary driver. The others are research Models and Services and teklad Laboratory Animal Products.

Who are HistoTox Labs's main competitors?

Broad incumbents on record are Inotiv, Labcorp Drug Development (formerly Covance), WuXi AppTec and Charles River Laboratories. Direct peers are Histo-Scientific Research Laboratories (HSRL), Seventh Wave Laboratories, Tox Path Specialists and Experimental Pathology Laboratories (EPL).

Does HistoTox Labs have an API?

No public API is recorded for HistoTox Labs.

What industry is HistoTox Labs in?

HistoTox Labs's product category is Contract Research / Preclinical Laboratory Services. Its primary akta.pro industry code is HLAGAFAI, Pathology & Histopathology Services, with a secondary code of HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals